Acetide 250 Tablet contains Acetazolamide 250mg, a carbonic anhydrase inhibitor primarily used in the management of glaucoma to reduce intraocular pressure. It is also indicated for treating edema associated with heart failure and certain forms of epilepsy.
This tablet falls under the ophthalmology and neurology segment, providing effective therapy for patients with increased intraocular pressure, fluid retention, or specific seizure disorders. Its oral formulation ensures convenient and consistent administration.
Acetide 250 Tablet is widely recommended by ophthalmologists, neurologists, hospitals, and clinics, making it a high-demand product for PCD pharma distribution. Its established clinical efficacy and safety profile make it a reliable prescription choice in specialized therapies.
For PCD pharma franchise and B2B partners, Acetide 250 Tablet represents a profitable and high-demand opportunity. Its inclusion in ophthalmology and neurology portfolios, steady prescription rate, and hospital demand ensure sustainable business growth, making it an attractive product for domestic and export markets.
Common side effects may include tingling of fingers and toes, mild nausea, loss of appetite, or drowsiness. Rarely, severe allergic reactions, electrolyte imbalance, or kidney stones may occur. Seek medical attention if serious symptoms develop.
Acetide 250 Tablet is indicated for glaucoma, edema associated with heart failure, altitude sickness, and certain types of seizures. It helps lower intraocular pressure, reduce fluid overload, and prevent acute mountain sickness.
Take Acetide 250 Tablet exactly as prescribed. Inform your doctor if you have kidney or liver disease, electrolyte imbalance, sulfonamide allergy, or are pregnant or breastfeeding. Do not exceed the recommended dose.
Store Acetide 250 Tablet in a cool, dry place below 25°C, protected from direct sunlight and moisture. Keep out of reach of children.